Stock Market

Novavax: ‘Substantial Doubt’ Around Ability to Continue


Covid-19 vaccine manufacturer


said Tuesday that there is “substantial doubt” about its ability to continue operating through this year.

In a quarterly earnings report issued after the market closed, the company said that it expects to have enough cash to fund its operations through the year, but that expectation is “subject to significant uncertainty” related to 2023 revenues, among other factors.


Share this news on your Fb,Twitter and Whatsapp

File source

Times News Network:Latest News Headlines
Times News Network||Health||

Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button